Success is an Outlier. Failure is a Pattern.
We don’t sell a map to the treasure; we sell a map of the minefield.
Fractional Corporate Development & Capital Strategy for Life Sciences Companies.
USD $15M+
Capital Strategy
Equity + Non-Dilutive Funding Secured
50%
Burn Rate Cut
Series B Scale-up
100%
MoM Growth
Post-Optimization
We Build with the Buy-Side in Mind
Most startups fail because they focus only on the science.
We reverse-engineer your roadmap based on what Investors and Acquirers actually buy.
Capital Strategy
We move beyond simple fundraising. We orchestrate dilutive and non-dilutive funding architectures (seed to C + Government Grants) to extend runway and minimize founder dilution.
Focus: Valuation Defense, Investor Analysis & Outreach.
M&A/Exit Readiness
We stress-test your assets against buy-side due diligence criteria (IP, Market Availability, Scalability) long before you enter the data room. We turn "deal killers" into structural assets.
Focus: Strategic Partnership Analysis & Outreach, Commercial Narrative.
Fractional Leadership
Advice is cheap; execution is rare. We embed as interim C-Suite operators, driving burn-rate efficiency and commercial traction without the friction of a full-time hire.
Focus: Burn Rate Reduction, Pipeline & R&D Optimization
The mustardseed. Edge
We bridge the gap between the Investors’ mandate and the Founder's reality.
We don’t sell theory; we sell scar tissue. Having navigated the "valley of death" firsthand, we have learned the hard lessons that kill most startups. We know exactly what the cliff edge looks like — and how to keep you from falling off it.
Combining this grit with buy- and sell-side experience, we now help founders secure capital and strategic partnerships, ensuring you build an asset engineered to survive and thrive.
Andrew Li - Founder & Managing Director